Navigation Links
OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
Date:2/11/2009

ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene") today announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community. With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.

Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation. With OriGene's China monoclonal antibody production capacity and these unique genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.

This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.

About OriGene

OriGene Technologies, Inc. is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies for research and drug discovery. Our flagship products are the world's largest cDNA and shRNA clone collections. Other key products include over 100,000 highly validated human tissues through its wholly owned subsidiary Cytomyx LLC., and its tissue derivative products tissue qPCR arrays for biomarker discovery and validation. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher would need for gene based research.

For more information, visit http://www.origene.com/antibody.


'/>"/>
SOURCE OriGene Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
2. New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers
3. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
4. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
5. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
6. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
7. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
8. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
9. Wound Management Technologies, Inc. Announces a Published Case Study
10. Cascades Technologies, Inc. Chosen to Deliver IT Support on a DoD Blast Injury Research Program
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
Breaking Biology Technology:
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):